Patents Assigned to MorphoSys AG
  • Patent number: 9090695
    Abstract: Monoclonal antibodies that act as potentiators, stimulators and agonists of guanylyl cyclase receptors are disclosed.
    Type: Grant
    Filed: November 17, 2009
    Date of Patent: July 28, 2015
    Assignee: MorphoSys AG
    Inventors: Alisa Waterman, Daniel Rajotte, Tobias Litzenburger, Alexandra Kraus
  • Publication number: 20150017160
    Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD38 antibody and lenalidomide and a pharmaceutical combination of an anti-CD38 antibody and bortezomib.
    Type: Application
    Filed: September 29, 2014
    Publication date: January 15, 2015
    Applicant: MORPHOSYS AG
    Inventors: Lisa Rojkjaer, Rainer Boxhammer, Jan Endell, Mark Winderlich, Christofer Samuelsson
  • Patent number: 8877899
    Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD38 antibody and lenalidomide and a pharmaceutical combination of an anti-CD38 antibody and bortezomib.
    Type: Grant
    Filed: September 26, 2011
    Date of Patent: November 4, 2014
    Assignee: Morphosys AG
    Inventors: Lisa Rojkjaer, Rainer Boxhammer, Jan Endell, Mark Winderlich, Christofer Samuelsson
  • Publication number: 20140255427
    Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a nitrogen mustard for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
    Type: Application
    Filed: August 14, 2012
    Publication date: September 11, 2014
    Applicant: MorphoSys AG
    Inventors: Jutta Amersdorffer, Stefan Steidl, Mark Winderlich, Susanne Krohn, Lisa Rojkjaer
  • Publication number: 20140227277
    Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a purine analog for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
    Type: Application
    Filed: August 14, 2012
    Publication date: August 14, 2014
    Applicant: MorphoSys AG
    Inventors: Jutta Amersdorffer, Stefan Steidl, Mark Winderlich, Susanne Krohn, Lisa Rojkjaer
  • Publication number: 20140205608
    Abstract: The present invention relates generally to a method for the treatment and/or prophylaxis of osteoarthritis (OA) and/or pain. In accordance with the present invention, an antagonist of c-Fms is effective in the treatment of osteoarthritis and/or pain. An antagonist of M-CSF includes, but is not limited to, an antibody that is specific for M-CSF, IL-34 or c-Fms.
    Type: Application
    Filed: July 17, 2012
    Publication date: July 24, 2014
    Applicants: MorphoSys AG, The University of Melbourne
    Inventors: Stefan Steidl, John Allan Hamilton, Andrew David Cook
  • Publication number: 20140206575
    Abstract: The present disclosure enables collections of variable heavy chain and variable light chain pairs comprising, in part, germline protein sequences that are pre-selected for functional properties relevant to developability, wherein the collections may be used to select against any antigen using, for example, phage display.
    Type: Application
    Filed: April 2, 2014
    Publication date: July 24, 2014
    Applicant: MorphoSys AG
    Inventors: Stefanie Urlinger, Thomas Tiller, Ingrid Schuster, Yvonne Stark
  • Publication number: 20140163208
    Abstract: The present disclosure enables methods of identifying the VH and VL class pairs in the human immune repertoire, determining the VH and VL class pairs that are most prevalent and those having favorable biophysical properties. More specifically, the collections of the present disclosure comprise the most prevalent and/or preferred VH and VL class pairings with highly diversified CDRs.
    Type: Application
    Filed: January 31, 2014
    Publication date: June 12, 2014
    Applicant: MorphoSys AG
    Inventors: Markus Enzelberger, Stefanie Urlinger, Thomas Tiller, Josef Prassler, Tanja Herrmann
  • Patent number: 8735099
    Abstract: New vectors expressible in a host comprising the promoter region of the melibiose operon operably linked to a transcriptional unit that includes nucleic acid sequence which is heterologous to the host. The expression of the nucleic acid sequence is controlled by the promoter region of the melibiose operon. The new vector can be used for the regulated heterologous expression of a nucleic acid sequence in a prokaryotic host. There is an isolated and purified nucleic acid sequence expressible in a host comprising the promoter region of the melibiose operon operably linked to a transcriptional unit that includes a nucleic acid sequence which is heterologous to the host. The expression of the nucleic acid sequence is controlled by the promoter region of the melibiose operon. A prokaryotic host is transformed with the vector or the isolated and purified nucleic acid sequence. There is a method for producing a polypeptide in a host using the vector.
    Type: Grant
    Filed: April 27, 2011
    Date of Patent: May 27, 2014
    Assignee: Morphosys AG
    Inventors: Johann Brass, Joachim Klein, Ralf Ostendorp
  • Patent number: 8728981
    Abstract: The present disclosure enables collections of variable heavy chain and variable light chain pairs comprising, in part, germline protein sequences that are pre-selected for functional properties relevant to developability, wherein the collections may be used to select against any antigen using, for example, phage display.
    Type: Grant
    Filed: November 18, 2011
    Date of Patent: May 20, 2014
    Assignee: MorphoSys AG
    Inventors: Stefanie Urlinger, Thomas Tiller, Ingrid Schuster, Yvonne Stark
  • Publication number: 20140120115
    Abstract: The present disclosure relates to antigen-binding moieties that specifically bind to MIF and D-DT and compositions and methods of use thereof.
    Type: Application
    Filed: July 13, 2012
    Publication date: May 1, 2014
    Applicant: MorphoSys AG
    Inventors: Swen Zierow, Juergen Klattig
  • Patent number: 8685896
    Abstract: The present disclosure enables methods of identifying the VH and VL class pairs in the human immune repertoire, determining the VH and VL class pairs that are most prevalent and those having favorable biophysical properties. More specifically, the collections of the present disclosure comprise the most prevalent and/or preferred VH and VL class pairings with highly diversified CDRs.
    Type: Grant
    Filed: May 29, 2010
    Date of Patent: April 1, 2014
    Assignee: MorphoSys AG
    Inventors: Markus Enzelberger, Stefanie Urlnger, Thomas Tiller, Josef Prassler, Tanja Herrmann
  • Publication number: 20140011698
    Abstract: The present invention provides methods, immunoassays, kits and devices pertaining to the detection of multiple biomolecules from single cells or other biological entities. It also enables the highly parallel detection of interacting biomolecules from such entities.
    Type: Application
    Filed: November 30, 2011
    Publication date: January 9, 2014
    Applicants: MorphoSys AG, ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG, HSG-IMIT Institut für Mikro-und Informationstechnik
    Inventors: Markus Enzelberger, Andreas Boll, Beate Diefenbach-Streiber, Guenter Roth, Felix von Stetten, Fabian Stumpf
  • Patent number: 8551733
    Abstract: The present invention provides methods to produce mixtures of exogenous proteins in single cells. Preferably said exogenous proteins are heteromeric and multimeric proteins, such as immunoglobulins. The method enables the controlled expression of proteins, thereby allowing the correct formation and assembly of multimeric proteins, such as immunoglobulins.
    Type: Grant
    Filed: February 8, 2010
    Date of Patent: October 8, 2013
    Assignee: MorphoSys AG
    Inventor: Markus Enzelberger
  • Publication number: 20130236902
    Abstract: The present disclosure enables collections of variable heavy chain and variable light chain pairs comprising, in part, germline protein sequences that are pre-selected for functional properties relevant to developability, wherein the collections may be used to select against any antigen using, for example, phage display.
    Type: Application
    Filed: November 18, 2011
    Publication date: September 12, 2013
    Applicant: MorphoSys AG
    Inventors: Stefanie Urlinger, Thomas Tiller, Ingrid Schuster, Yvonne Stark
  • Patent number: 8513164
    Abstract: The present invention relates to a method of identifying one or more genes encoding one or more proteins having an optimized property. In particular, the method comprises expressing a collection of genes and screening for a desired property, identifying a plurality of genes having the desired property, and replacing one or more one or more sub-sequences of each of said genes with a different, compatible genetic sub-sequence, and screening again in order to identify genes encoding proteins having an optimized property.
    Type: Grant
    Filed: December 21, 2006
    Date of Patent: August 20, 2013
    Assignee: MorphoSys AG
    Inventors: Achim Knappik, Peter Pack, Liming Ge, Simon Moroney, Andreas Plückthun
  • Patent number: 8486394
    Abstract: The present invention provides novel antibodies and functional fragments thereof specific for CD38, and methods of using the same for the treatment of diseases associated with CD38 expression, including hematological malignancies such as multiple myeloma.
    Type: Grant
    Filed: November 8, 2011
    Date of Patent: July 16, 2013
    Assignee: Morphosys AG
    Inventors: Michael Tesar, Ute Jäger
  • Publication number: 20130136747
    Abstract: The present invention relates to antibody molecules capable of specifically recognizing two regions of the ?-A4 peptide, wherein the first region comprises the amino acid sequence AEFRHDSGY as shown in SEQ ID NO: 1 or a fragment thereof and wherein the second region comprises the amino acid sequence VHHQKLVFFAEDVG as shown in SEQ ID NO: 2 or a fragment thereof. Furthermore, nucleic acid molecules encoding the inventive antibody molecules and vectors and hosts comprising said nucleic acid molecules are disclosed. In addition, the present invention provides for compositions, preferably pharmaceutical or diagnostic compositions, comprising the compounds of the invention as well as for specific uses of the antibody molecules, nucleic acid molecules, vectors or hosts of the invention.
    Type: Application
    Filed: November 8, 2012
    Publication date: May 30, 2013
    Applicants: MORPHOSYS AG, HOFFMANN-LA ROCHE INC.
    Inventors: Hoffmann-La Roche Inc., Morphosys AG
  • Patent number: 8367586
    Abstract: The present disclosure enables collections of variable heavy chain and variable light chain pairs comprising, in part, germline protein sequences that are pre-selected for functional properties relevant to developability, wherein the collections may be used to select against any antigen using, for example, phage display.
    Type: Grant
    Filed: November 18, 2011
    Date of Patent: February 5, 2013
    Assignee: MorphoSys AG
    Inventors: Stefanie Urlinger, Thomas Tiller, Ingrid Schuster, Yvonne Stark
  • Publication number: 20130030157
    Abstract: The present invention provides synthetic rodent antibody libraries, such as mouse or rat antibody libraries, as well as polypeptides, nucleic acids, vectors, host cells and methods used in conjunction with these libraries. The present invention also provides antibodies isolated from such libraries and variants of such antibodies.
    Type: Application
    Filed: January 28, 2011
    Publication date: January 31, 2013
    Applicant: MORPHOSYS AG
    Inventors: Josef Prassler, David Ott, Stefanie Thiel, Yvonne Stark, Ute Keck, Thomas Pietzonka, Hilmar Ebersbach